A modified nucleoside compound and oligonucleotides made therefrom

CN122122164APending Publication Date: 2026-05-29CHENGDU BETERIMA BIOMEDICAL TECHNOLOGY CO LTD +1
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
CHENGDU BETERIMA BIOMEDICAL TECHNOLOGY CO LTD
Filing Date
2024-09-25
Publication Date
2026-05-29

AI Technical Summary

Technical Problem

The bioavailability and pharmacokinetic properties of existing oligonucleotide drugs in vivo are insufficient, making it difficult to effectively regulate target mRNA expression.

Method used

A modified nucleoside compound is developed to improve its activity and enzyme resistance by introducing 2’, 3’-phosphate-linked nucleotides (4’-modified TNAs) into the oligonucleotides, as well as improve cell membrane penetration and organ targeting.

Benefits of technology

It improves the activity and enzyme cleavage resistance of oligonucleotides, enhances its enrichment degree and pharmacokinetic properties in the target organ, and improves bioavailability and efficacy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000196_0000
    Figure 00000196_0000
  • Figure 00000196_0001
    Figure 00000196_0001
  • Figure 00000196_0002
    Figure 00000196_0002
Patent Text Reader

Abstract

A nucleoside phosphoramidite compound, the compound being a 2'-phosphoramidite group, 4'-modified TNA structured compound. The nucleoside phosphoramidite compound can be used to incorporate into the first and / or last and / or intermediate of an oligonucleotide such that the modified oligonucleotide hybridizes to a portion of a target mRNA, thereby causing a loss or down-regulation of normal function of the target mRNA.
Need to check novelty before this filing date? Find Prior Art